It is clinically accepted that the administration of a tissue plasminogen activator (t-PA) for clot dissolution—alone or in combination with surgical procedures such as endovascular thrombectomy for clot retrieval—constitute the most acceptable treatment to treat stroke patients in the early stages (acute phase). This evidence concerns the gene PLAT and stroke disorder.